Ryan Scott

Ryan Scott joined MJH Life Sciences in 2021. In addition to writing and editing timely news and article coverage, she manages OncLive's social media accounts; check us out @onclive across platforms such as LinkedIn, Facebook, X, and Instagram! She also attends conferences live and virtually to conduct video interviews and produce written coverage. Email: rscott@onclive.com

Articles

Rates of Taxane-Induced Peripheral Neuropathy Underscore Need to Tailor Treatment for Black Patients With Early Breast Cancer

October 31st 2024

Docetaxel treatment was associated with significantly less taxane-induced peripheral neuropathy vs paclitaxel in Black patients with breast cancer.

Sacituzumab Tirumotecan NDA for Pretreated EGFR+ NSCLC Accepted for Review in China

October 31st 2024

An NDA seeking the approval of sacituzumab tirumotecan for EGFR-mutant non–small cell lung cancer is under review by the NMPA’s CDE.

Sugemalimab Plus Chemotherapy Earns UK Approval in First-Line Metastatic NSCLC

October 31st 2024

First-line sugemalimab plus chemotherapy has received UK approval for metastatic NSCLC without EGFR-sensitizing mutations or ALK/ROS1/RET alterations.

Patient Communication is Key to Delivering Optimal PARP Inhibitor Treatment in Ovarian Cancer

October 30th 2024

Laura J. Chambers, DO, discusses the roles of niraparib and olaparib in ovarian cancer and the importance of patient communication throughout treatment.

Breast Cancer Awareness Month Spotlights Progress With Personalized Medicine

October 30th 2024

Sheldon M. Feldman, MD, discusses the importance of personalized medicine in breast cancer during Breast Cancer Awareness Month.

The Future of Hematologic Cancer Care Shifts Toward Personalized and Chemotherapy-Free Regimens

October 29th 2024

Daniel DeAngelo MD, PhD, discusses the evolution of management strategies and treatment goals across several hematologic malignancies.

Rezatapopt Monotherapy Remains Under Study Following Discontinuation of Combination Cohort in TP53+ Solid Tumors

October 28th 2024

PMV Pharmaceuticals has provided an update on the PYNNACLE trial investigating rezatapopt in TP53 Y220C–mutated solid tumors.

QOL Remains Key Consideration for First-Line Treatment of Anemia in Lower-Risk MDS

October 28th 2024

Jorge Cortes, MD, discusses the need to balance outcomes and quality of life in the treatment of anemia in low-risk myelodysplastic syndrome.

RMC-9805 Triggers Tumor Regressions in KRAS G12D–Mutant Pancreatic Cancer

October 28th 2024

RMC-9805 was proven safe and active in patients with previously treated, KRAS G12D–mutant pancreatic ductal adenocarcinoma.

The WEE1 Inhibitor APR-1051 Shows Early Safety and Tolerability in Advanced, Mutated Solid Tumors

October 25th 2024

Treatment with APR-1051 appears safe and well tolerated in patients with advanced solid tumors and select cancer-associated gene alterations.

Nivolumab Plus AVD Prolongs PFS vs Brentuximab Vedotin Plus AVD in Advanced-Stage Hodgkin Lymphoma

October 25th 2024

Nivolumab plus AVD prolonged median PFS vs brentuximab vedotin plus AVD in patients with stage III or IV advanced-stage classic Hodgkin lymphoma.

Dr Miller on the Efficacy of Selinexor in TP53 Wild-Type Endometrial Cancer

October 25th 2024

David S. Miller, MD, discusses the efficacy of selinexor in patients with advanced or recurrent TP53 wild-type endometrial cancer.

ODAC Votes on PD-1 Inhibitors Underscore Importance of Biomarker Testing in Gastric/GEJ and Esophageal Cancers

October 25th 2024

Nataliya Uboha, MD, PhD, discusses the evolving treatment landscape for patients with gastric, gastroesophageal junction, and esophageal cancers.

2024 Regulatory Approvals Across NSCLC Propel the Therapeutic Landscape Forward

October 24th 2024

Noman Ashraf, MD, discusses the evolving treatment landscape in non–small cell lung cancer following numerous regulatory approvals in the space.

Investigative Targeted Agents Are Set to Expand the BCG-Unresponsive NMIBC Treatment Paradigm

October 24th 2024

Yair Lotan, MD, discusses notable up-and-coming agents in the BCG-unresponsive non–muscle-invasive bladder cancer treatment armamentarium.

Telisotuzumab Adizutecan Delivers Early Signals of Antitumor Activity in CRC

October 23rd 2024

John H. Strickler, MD, discusses treatment with telisotuzumab adizutecan for CRC as well as this ADC’s potential to broaden the CRC treatment paradigm.

ADCs Redefine HER2+ NSCLC Landscape With Potential to Shift to the Frontline Setting

October 23rd 2024

Noman Ashraf, MD, discusses data with T-DXd in HER2-mutated and -overexpressing lung cancer populations and next steps with ADC combination therapies.

FDA Approves Companion Diagnostic for Zolbetuximab in CLDN18.2+ Gastric/GEJ Cancer

October 22nd 2024

The FDA has approved the Ventana CLDN18 (43-14A) RxDx Assay as a companion diagnostic for zolbetuximab in CLDN18.2-positive gastric/GEJ cancer.

BCG-Unresponsive NMIBC Management Begins to Shift Away From Bladder Removal

October 22nd 2024

Yair Lotan, MD, discusses the treatment paradigm for BCG-unresponsive NMIBC, approved therapeutic options, and factors that influence treatment decisions.

FDA Accepts NDA Resubmission for First-Line Rivoceranib/Camrelizumab Combo in Unresectable HCC

October 21st 2024

The FDA has accepted the new drug application resubmission for the first-line combination of rivoceranib plus camrelizumab in unresectable HCC.